Dharmani, Charles
Bonafede, Machaon
Krivoshik, Andrew
Funding for this research was provided by:
Astellas Pharma, Inc. and Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, the co-developers of enzalutamide
Article History
First Online: 13 October 2017
Compliance with Ethical Standards
: This article does not report on any studies with human participants or animals performed by any of the authors.
: Charles Dharmani is an employee of Astellas. Machaon Bonafede is an employee of Truven Health Analytics, an IBM Company, which was awarded a research contract to conduct this study with and on behalf of Astellas Pharma, Inc. Andrew Krivoshik is an employee of Astellas and holds stock in AbbVie and Abbott.
: This study was funded by Astellas Pharma, Inc. and Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, the co-developers of enzalutamide. Medical writing assistance and editorial support, funded by both sponsor companies, was provided by Mei Lye and Lauren Smith from Complete HealthVizion.